Can Quantitative Monitoring of B Cells In Primary Demyelinating CNS Disorders Evaluate Safety And Efficacy Of Rituximab?

INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a) Patients receiving maintenance Rituximab therapy for primary CNS demyelinating disorder (diagnosed as per accepted criteria for MS and NMOSD) as disease modifying therapy to prevent relapse.
•b) Willing to provide written informed consent.

•i)Pregnant and Lactating females
•ii)Patients with history of angina, arrhythmia, congestive cardiac failure (NYHA III and IV)
•iii)Patients with HIV, HBV or HCV infection
•iv)Patients with unevaluated abdominal pain with possibilities of bowel perforation or obstruction.
•v)Untreated concurrent infections (mucocutaneous, respiratory, genitourinary etc)
•vi)Recent vaccinations

发起方

INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA